Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

FDA clears IND for phase I study of DA-01 in advanced Parkinson's disease

Jan. 11, 2021

Part 1 topline data reported from trial of SRP-9001 in Duchenne muscular dystrophy

Jan. 8, 2021

Phase III RISE trial of TV-46000 in schizophrenia meets primary endpoint

Jan. 8, 2021

Extension study results of patisiran in transthyretin-related amyloid polyneuropathy presented

Jan. 8, 2021

ApoE multitasks for regulating brain lipids

Jan. 8, 2021

Endpoints met in phase Ib/II trial of BXCL-501 for agitation in dementia

Jan. 7, 2021

Dana-Farber Cancer Institute presents new HDAC3 inhibitors

Jan. 7, 2021

Luye initiates phase I trial of monthly microsphere injection LY-03009

Jan. 5, 2021

Karuna opens enrollment in phase III study of KarXT in acutely psychotic schizophrenia

Jan. 5, 2021

AXS-07 provides durable migraine pain relief in phase III MOVEMENT trial

Jan. 4, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 21, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...